Imco product line undergoes name changeEchoing recent changes in its corporate ownership, Imco Technologies (formerly Rogan Medical Systems Inc.) has relaunched its entire product line with a new name: Imco-Rad. All of the Pewaukee, WI-based
Echoing recent changes in its corporate ownership, Imco Technologies (formerly Rogan Medical Systems Inc.) has relaunched its entire product line with a new name: Imco-Rad. All of the Pewaukee, WI-based firms offerings previously carried the prefix Hyper (as in HyperPACS and HyperView), which Imcos former parent company, Rogan Medical Systems BV, continues to use.
Many of the Imco products also feature new enhancements. For example, Imco-Rad Digitizer now supports digitizers from Lumisys, GSi Lumonics, Howtek, and Vidar; ImcoRad Archive now supports CD, DVD, MOD, DLT, and AIT media; and Imco-Rad Teleradiology now supports wavelet compression in addition to JPEG.
Rogans U.S. subsidiary became Imco following a management buyout late last year (PNN 2/00). Rogan continues to serve as a strategic supplier to Imco, while Imco is a nonexclusive distributor for Rogan. Rogan is selling its products primarily in Europe, while Imco is concentrating on the U.S. market. The two firms are also continuing some joint product and technology development.
© 2000 Miller Freeman, Inc., a United News & Media company.
New Study Assesses Benefits of High-Resolution Photon-Counting for Computed Tomography Angiography
October 10th 2024Researchers found that ultra-high resolution photon-counting significantly enhanced visualization of small vessels and facilitated improved reduction of blooming artifacts for head and neck computed tomography angiography (CTA) scans.
Multicenter Study Identifies Key Factors Associated with Mammogram-Occult Ipsilateral Breast Cancer
October 9th 2024A symptomatic first breast cancer diagnosis, prevailing breast density at a second breast cancer diagnosis and trabecular thickening on surveillance mammography were linked to mammogram-occult ipsilateral breast cancer, according to new research.